UK/Ireland first NovoSorb BTM Surgeries
January 28 2020
PolyNovo is pleased to announce NovoSorb BTM been applied to the first two patients in the UK.
Read more
January 28 2020
PolyNovo is pleased to announce NovoSorb BTM been applied to the first two patients in the UK.
Read more
January 22 2020
PolyNovo has received its first orders of BTM from PMI for use in Germany, Austria and Switzerland with the first patient being treated in Germany on Sunday.
January 7 2020
PolyNovo has achieved its first two-million-dollar-month of sales in December 2019.
Read more
December 16 2019
PolyNovo has supplied NovoSorb BTM to hospitals in New Zealand and Australia. The surgical and nursing teams have established clinical expertise in the use of NovoSorb BTM ensuring the best clinical outcomes for these patients.
Read more
December 13 2019
PolyNovo is pleased to announce NovoSorb BTM has been granted a certificate of conformance (CE Mark) approval for sale throughout UK/Ireland and the European Union.
Read more
October 31 2019
PolyNovo has been named 'Company of the Year' in the AusBiotech and Johnson & Johnson Innovation Industry Excellence Awards at AusBiotech 2019.
Read more
October 27 2019
PolyNovo is delighted to announce the appointment of Dr Robyn Elliott to the board of directors as Non-Executive Director.
Read more
August 15 2019
PolyNovo is pleased to announce the successful registration of NovoSorb BTM with the Health Sciences Authority of Singapore
Read more
June 27 2019
PolyNovo Investor's Update
Macquarie Emerging Leaders Forum, Melbourne 19-20th June 2019.
May 6 2019
PolyNovo is delighted to announce the appointment of Mr Ashok Srinivasan to the position of Chief Operating Officer (“COO”), with responsibility for the Company’s operations, including manufacturing, engineering, supply chain and facilities.
Read more
May 2 2019
PolyNovo is pleased to announce revenue from BTM sales for the month of April were more than $1M.
Read more
May 1 2019
PolyNovo has been granted access to the US Department of Defense (DoD) contracts through a Defense Acquisition and Program Administration (DAPA) and Veteran’s Affairs (VA) contract.
April 29 2019
PolyNovo is pleased to announce the appointment of the German company PolyMedics Innovations (PMI) as distributor for NovoSorb BTM in Germany, Austria and Switzerland.
Read more
April 29 2019
PolyNovo is pleased to announce that Mr Kevin Whitely has started as Vice President of PolyNovo North America LLC.
Read more
April 23 2019
PolyNovo is pleased to announce the first ever poster presentation detailing the use of NovoSorb BTM in Diabetic Foot and Venous Leg Ulcers.
Read more
April 8 2019
PolyNovo’s CEO Paul Brennan will make the attached presentation to Fund Managers in New York on Monday 8 and Tuesday 9 April. The presentation outlines, among other things, PolyNovo’s new product pipeline development.
January 18 2019
PolyNovo is pleased to announce the successful registration of NovoSorb BTM with the Medical Device Authority of Malaysia. This regulatory approval is the first of several Asian regulatory registrations anticipated.
January 18 2019
PolyNovo wishes to announce the purchase of an adjoining office/warehouse facility. The intention is to combine the facilities and buildings allowing an expanded production facility suitable for several years.
December 12 2018
PolyNovo is pleased to announce the appointment of Mr Jan-Marcel Gielen as Chief Financial Officer and Company Secretary efffective 12 December.
Read more
November 1 2018
PolyNovo is pleased to announce regulatory approval for the sale of NovoSorb BTM (NovoDerm) in India and the signing of Myovatec Surgical Systems Pvt Ltd (Myovatec) as its distributor.
August 14 2018
PolyNovo is pleased to announce that the NovoSorb BTM device is now entered in the TGA ARTG (Australian Register for Therapeutic Goods) following Conformity Assessment review via the Priority Review Designation pathway.
August 2 2018
PolyNovo is pleased to announce that the last patient has been enrolled in the NovoSorb® Biodegradable Temporising Matrix (BTM) Full Thickness Burn feasibility clinical trial being conducted in the USA.
July 28 2018
PolyNovo is pleased to announce regulatory approval for NovoSorb BTM to be sold in Saudi Arabia and the signing of Al Mofadaly as its exclusive distributor.
July 26 2018
The Melbourne company PolyNovo Ltd has offered its life changing product for the use on burns victims in Greece. The company's NovoSorb® BTM has been offered to the surgical teams caring for patients burnt in the fires.
May 22 2018
PolyNovo is pleased to announce that the last patient has been enrolled in the NovoSorb BTM Full Thickness Burn clinical trial.
Read more
April 18 2018
PolyNovo congratulates Prof John Greenwood and Dr Marcus Wagstaff on winning “Best in Category- Wounds” for their Poster at the American Burn Association (ABA) meeting in Chicago.
April 3 2018
PolyNovo Ltd is pleased to announce the signing of the project plan for the development of a range of breast products with Establishment Labs (EL).
Read more
March 20 2018
PolyNovo has been featured in the quarterly journal, the Australian Business Executive. A printed journal can be obtained through TheABE.com.au website/ subscription.
Read more
January 23 2018
PolyNovo Ltd is pleased to announce the appointment of Greg Lewis to a new combined role of COO, CFO and Company Secretary.
Read more
January 17 2018
PolyNovo Ltd is pleased to announce the signing of a heads of agreement with Establishment Labs, a global medical device company focused on breast aesthetics and reconstruction technologies.
Read more
December 14 2017
PolyNovo Ltd is pleased to release the presentation to be given by CEO Paul Brennan and Chairman David Williams to Hong Kong institutional investors today.
Read more
November 21 2017
PolyNovo Ltd is pleased to release the presentation to be given by CEO Paul Brennan today at the Financial News Network (FNN) CEP Sessions in Melbourne.
Read more
October 27 2017
PolyNovo Limited advises that its Share Purchase Plan has closed. The Company is delighted with the response to the SPP offer resulting in applications for 59.4 million new shares and raising $16.0 million.
Read more
October 20 2017
Ms Andrea Goldie has resigned as Company Secretary effective 18 October 2017.
Read more
October 15 2017
PolyNovo is delighted to announce the signing of a Memorandum of Understanding (MOU) with an innovative global medical device company for the development of a range of breast devices based on the NovoSorb polymer technology.
Read more
October 4 2017
PolyNovo is pleased to announce the signing of AMI Medical Technologies Ltd (AMI) as its distributor for the company’s NovoSorb™ BTM (Biodegradable Temporising Matrix) in Israel.
Read more
September 26 2017
We are pleased to announce we have successfully completed a placement to professional and sophisticated investors to raise $7 million at $0.27 per share.
Read more
September 1 2017
PolyNovo is delighted to announce the first sales of NovoSorb BTM to one of the major hospitals in the US.
Read more
June 2 2017
PolyNovo is pleased to announce that the Royal College of Surgeons (UK) have published Professor John Greenwood’s 2016 Hunterian Lecture. This paper outlines the evolution of burn care and the potential shift in patient care through the development of NovoSorb BTM (Biodegradable Temporizing Matrix).
May 12 2017
PolyNovo has been collaborating with Beta Cell Technologies Pty Ltd (“Beta Cell”) from Adelaide on a research project exploring the potential of integrated NovoSorb™ BTM to host pancreatic islets in the skin.
April 11 2017
PolyNovo Limited is pleased to release the presentation to be given by CEO Paul Brennan today at the ASX CEO Sessions in Sydney.
Read more
February 22 2017
PolyNovo Limited (“PolyNovo”) is pleased to announce the first US patient has been treated with our Biodegradable Temporising Matrix (BTM).
Read more
February 21 2017
PolyNovo Limited (“PolyNovo”) is pleased to announce our first Biodegradable Temporising Matrix (BTM) order in South Africa.
Read more
December 8 2016
Tony Lowther MD of Ascendis Medical attended the PolyNovo office for the signing of the agreement. It is great to have Tony and his Team working with PolyNovo.
Read more
December 2 2016
PolyNovo is pleased to announce the appointment of Owens and Minor (O&M) as its strategic logistics partner (3PL) in the United States (US).
Read more
October 10 2016
PolyNovo & Device Technologies distribution agreement.
Read more
October 3 2016
PolyNovo announces the direct market entry into the US market with our own sales team.
Read more
August 16 2016
New Branding/Logo reflecting our move towards a commercial enterprise.
Read more
July 29 2016
This Adelaide newspaper article outlines how the technologies may address some aspects of diabetes treatments in the future.
Read more
July 27 2016
Adelaide Ch:10 TV article on the BTM use in Diabetes research.
Read more
June 14 2016
PolyNovo is pleased to be a silver sponsor of the 2017 ANZBA (Burns) Conference being held in Adelaide in October 2017.
Read more
May 31 2016
ASX Announcement of the start of the BARDA funded feasibility trials in US.
Read more
May 3 2016
A newsletter write up of PolyNovo and the changes in focus over the past 18 months.
Read more
May 3 2016
ASX Announcement of the start of the BARDA funded feasibility trials in US.
Read more
April 30 2016
This is the synchronized slide presentation from the ASX/FNN CEO Sessions in Melbourne 19 April.
Read more
February 1 2016
PNV is a Melbourne based medical device company that designs and manufactures solutions for its NovoSorb biodegradable polymer technology.
Read more
February 1 2016
PNV is a Melbourne based medical device company that designs and manufactures solutions for its NovoSorb biodegradable polymer technology.
Read more